We examined cytotoxic effects of adenoviruses (Ad) expressing the p53 gene (Ad-p53) in nine human esophageal carcinoma cell lines with respect to the Ad receptor expression and the endogenous p53 gene status. Ad-p53-mediated cytotoxicity was related with an expression level of the coxsackievirus adenovirus receptor (CAR) but not with that of CD51, both of which are type 5 Ad receptors. Contrary to earlier studies, we found that the cytotoxicity was greater in tumor cells with the wild-type p53 gene than in those with mutated p53. The cytotoxic activity of Ad defective of E1B55kDa molecules (Ad-delE1B55), however, was not linked with the CAR expression level or the endogenous p53 status. We noticed that the tumor cells with the wild-type p53 gene showed greater CAR expression levels, although transduction with Ad-p53 did not upregulate the CAR expression in the mutated cells. We also examined the Ad-53-mediated cytotoxicity in two kinds of paired fibroblasts, parent and immortalized with loss of the p53 functions, and showed that the CAR expression level was more influential than the endogenous p53 status in the cytotoxicity. These data suggest that CAR expression level is a better predictive marker than endogenous p53 status for Ad-p53-mediated cytotoxicity in esophageal carcinoma.
Introduction
Esophageal carcinoma is an intractable disease and curative surgical operation is often difficult for aged and extended cases. 1 Gene therapy is a possible novel strategy that can potentially improve the prognosis and quality of life of the patients. Adenoviruses (Ad) bearing the human wild-type p53 gene (Ad-p53) have been clinically examined for feasibility and a number of patients of squamous cell carcinoma of head and neck have received the Ad-p53 treatment. 2 In contrast, esophageal carcinoma, another representative squamous cell carcinoma developed adjacent to a neck region, has not been well investigated for susceptibility to Ad-p53. We reported that Ad-p53 produced cytotoxic effects for esophageal carcinoma cells and have recently completed a phase I/II clinical trial for cancer patients with Ad-p53. 3, 4 The clinical study showed that intratumoral injection of Ad-p53 was safe and produced antitumor effects with variable efficacy. 4 Multiple mechanisms of the Ad-p53-mediated antitumor activities are well demonstrated and apoptosis induction is one of the direct actions of tumors. 5 Ad defective of E1B55 kDa molecules (Ad-delE1B55) have been also investigated for clinical feasibility in various cancer types including head and neck cancer. 6 Ad-delE1B55 replicate preferentially in tumors and subsequently induce tumor cell death but none of the clinical studies for esophageal carcinoma with Ad-delE1B55 has been reported.
Both Ad-53 and Ad-delE1B55 belong to the group C type 5 Ad, which use primarily the coxsackievirus and adenovirus receptor (CAR) and secondly a v b 3 and a v b 5 integrins expressed on target cells as their receptors. 7 CD51 is the a v -chain of integrin, which constitutes the heterodimers with integrin b 3 -(CD51/CD61) and other integrin b-chains. The expression of CAR in human tumors is often downregulated and consequently decreased CAR expression hampers Ad-mediated gene transfer and the antitumor effects. 8 Earlier studies also showed that a status of the endogenous p53 gene in targeted tumors influenced the outcomes of the Ad-p53-mediated antitumor effects. 9, 10 Transduction of the wildtype p53 gene produced better therapeutic effects in tumors with p53 mutation than those with the wild-type p53, although the effects were in some reports independent of the p53 status. 11, 12 The tumor specificity of AddelE1B55 was initially reported to be associated with p53 mutation, 13 but subsequent studies showed that AddelE1B55-mediated cytotoxicity was not linked with the p53 status despite the p53-binding activity of the E1B55kDa molecules.
14 A recent study suggest that it could be partly due to a novel function of the E1B molecules, which supports the viral replication in tumors. 15 In any event, it is beneficial to have a biomarker to predict the efficacy before the treatment in clinical settings. In this study, we analyzed the cytotoxicity of Ad-p53 and Ad-delE1B55 with respect to CAR expression and the p53 status in nine human esophageal carcinoma cells and found that Ad-p53-but not Ad-delE1B55-mediated cytotoxicity was correlated with the CAR expression level and that Ad-p53 produced better cytotoxicity to the tumors with the wild-type p53 gene.
Materials and methods

Cells
Human esophageal carcinoma cells, TE-1, TE-2, TE-10, TE-11, YES-2, YES-4, YES-5, YES-6 and T.Tn, two kinds of paired human fibroblasts and their immortalized cells, OUMS-24 and OUMS-24/P6X, 16 and HFF and IF, 17 which were generated by expressing dominantnegative p53 and E6/E7 of type 16 papilloma viruses, respectively, were cultured with RPMI 1640 medium supplemented with 10% fetal calf serum.
Receptor expression
Cells were stained with either anti-CAR antibody (Upstate, Charlottesville, VA) or antihuman CD51 antibody (Chemicon, Temecula, CA) followed by fluorescein isothiocyanate-conjugated antimouse immunoglobulin-G antibody, and were analyzed for their fluorescence intensity with FACScan (BD Biosciences, San Jose, CA) and CellQuest software (BD Biosciences). Mean fluorescence intensity of the staining profile was expressed as an arbitrary FL1 unit after standardized with the intensity by the second antibody as 10 in the unit.
Ad preparation
Ad-p53 and Ad expressing the b-galactosidase gene (AdLacZ) or green fluorescent protein gene (Ad-GFP) were prepared with an Adeno-X expression system (Takara, Shiga, Japan). Ad-delE1B55 were also constructed as described. 13 Expression of the p53, the b-galactosidase and the GFP genes is controlled with the same cytomegalovirus promoter. Ad were propagated in HEK293 cells and the Ad titers were determined with the tissue culture infectious dose.
In vitro cytotoxicity Cells (5 Â 10 3 per well) were seeded in 96-well plates and were cultured for 5 days with Ad at a different multiplicity of infection (MOI). Viable cell numbers in each well were measured with a cell-counting WST kit (Wako, Osaka, Japan). The amount of formazan produced in each well was determined with the absorbance at 450 nm. Percent cell survival was calculated on the basis of the absorbance without treatments.
Infectivity of Ad
Cells were infected with Ad-GPF for 30 min and were washed to remove Ad. They were cultured for 2 days and were analyzed for the GFP-positive cell populations with FACScan and CellQuest software. Cell populations that showed fluorescence greater than the brightest 5% of uninfected cells were judged as positively stained.
Western blot analysis
Cells were treated with Ad-p53, cisplatin (Wako) or etoposide (Sigma-Aldrich, St Louis, MO), and the cell lysates were subjected to SDS-polyacrylamide gel electrophoresis. The protein was transferred to a nylon filter and was hybridized with antibodies against p53 (Lab Vision, Fremont, CA), p21 (Santa Cruz Biotech, Santa Cruz), actin (Sigma-Aldrich) or GAPDH (glyceraldehydes 3-phosphate dehydrogenase; Abcam, Cambridge, UK). The membranes were developed with the ECL system (GE Healthcare, Buckinghamshire, UK).
Statistical analysis
Statistical analyses were carried out with analysis of variance and were based on correlation coefficient (CC). P-values o0.05 are considered as statistically significant.
Results
Expression of Ad receptors and p53 status
We examined CAR expression levels of human esophageal carcinoma cells with flow cytometry and found that the expression level was variable among the cells tested (Figures 1a and b) . Moreover, all the cells expressed the CAR at a low level compared with that of HEK293 cells. CD51 is a vitronectin receptor a v -chain and is associated with integrin b 3 and b 5 to constitute heterodimers, and the anti-CD51 antibody used in this study recognized a v b 3 and a v b 5 integrins. The CD51 expression level was also variable and lower than that of HEK293 cells except TE-10 and T.Tn cells.
We also determined the status of the p53 gene with a direct sequencing technique and found that four cell lines had the wild-type p53 gene and five lines had the mutation, which generated amino-acid changes (Table 1) .
Cytotoxic activity of Ad-p53 and Ad-delE1B55
We examined cytotoxic activities of Ad-p53 and AddelE1B55 on esophageal carcinoma cells ( Figure 2 ). All the cells except T.Tn cells were sensitive to Ad-p53, and Ad-delE1B55 were cytotoxic to all of them. The cytotoxicity was MOI-dependent and Ad-LacZ as a control did not inhibit cell survival except T.Tn cells at 250 MOI. The cytotoxic activity of Ad-delE1B55 was greater than that of Ad-p53 in most of the cells at high MOI (MOI ¼ 250, P ¼ 0.064), whereas YES-4 cells showed similar sensitivity to Ad-p53 and Ad-delE1B55, and YES-6 cells were more susceptible to Ad-p53 than Ad-delE1B55 at 250 MOI.
Relation between expression of Ad receptors and cytotoxic activity
We investigated the relation between Ad-mediated cytotoxicity and the CAR expression level to examine a possible influence of the receptor expression on the cytotoxicity (Figure 3a) . We classified the cells into three groups according to the CAR expression level (Figure 1b ): TE-11, YES-4 and YES-6 were CAR-high (mean arbitrary fluorescence intensity: 26.5±2.31 (s.e.)), TE-2, TE-10 and YES-5 were CAR-middle (16.5±1.40), TE-1, YES-2 and T.Tn were CAR-low (4.96 ± 2.43). The expression levels of the three groups are statistically different (CAR-high and CAR-middle, P ¼ 0.015; CARmiddle and CAR-low, P ¼ 0.0082). We used the percent survival of respective cells treated with Ad at 250 MOI ( Figure 2 ) as a representative of the Ad-mediated cytotoxicity and found that the Ad-p53-mediated cytotoxic activity was linked with the CAR levels (CC, P ¼ 0.0008; CAR-high and CAR-low, P ¼ 0.018; Figure 3a ). In contrast, the Ad-delE1B55-mediated cytotoxicity was not correlated with the CAR level (CC, P ¼ 0.23). The CD51 expression level was not linked with the CAR level (P ¼ 0.22); accordingly, it was not subjected to the CAR grouping (CAR-high and CARlow, P ¼ 0.17; Figure 3a ). The CD51 level had no relation with the cytotoxicity mediated by Ad-p53 (CC, P ¼ 0.089) or Ad-delE1B55 (P ¼ 0.87). The CAR expression level thus influenced the cytotoxic activity with Ad-p53 but not with Ad-delE1B55.
Relation between p53 status and cytotoxic activity We examined correlation between the p53 status and the Ad-mediated cytotoxicity or the Ad receptor expressions (Figure 3b ). We found that esophageal carcinoma cells with the wild-type p53 gene were more sensitive to Ad-p53 than those with the mutated gene (P ¼ 0.073), but such differential susceptibility was not observed in AddelE1B55-mediated cytotoxicity (P ¼ 0.47). In addition, cells bearing the wild-type p53 showed significantly greater CAR expression levels than those with the mutation (P ¼ 0.0047), but we did not observe any correlation between the p53 status and the CD51 expression level (P ¼ 0.11). A multiple comparison test showed that CAR expression levels were liked with the p53 status (Scheffe's analysis, P ¼ 0.0015) and the p53 status was also inked with the Ad-p53-mediated cytotoxicity (Scheffe's analysis, P ¼ 0.021). These analyses raised a possible linkage of the cytotoxicity not only with the CAR expression level but also with the p53 gene status. 
CAR-dependent Ad-p53 effects G Ma et al
Influence of CAR or p53 status to Ad-p53 effects These analyses collectively suggest that tumors with the wild-type p53 gene tend to express CAR at a high level and consequently are susceptible to Ad-p53-mediated cytotoxicity compared with those with mutated p53 genes. We firstly examined a possible p53-mediated modulation of CAR expression as the expression level was greater in tumors with the wild-type p53 gene, which encoded a transcriptional factor for a number of genes. We transduced TE-10 and YES-5 cells with Ad-p53, both of which express CAR at a middle level and have the p53 mutation. Transduction with Ad-p53 increased p53 protein in respective cells (Figure 5a ), but the CAR (Figure 5b ) and the CD51 (data not shown) expression levels remained unchanged, showing that p53 did not upregulate the CAR expression. We then examined whether the CAR expression level or the endogenous p53 status was more influential to Adp53-mediated cytotoxicity. We used two kinds of paired cell lines-normal fibroblasts and the immortalized cells; OUMS-24 and OUMS-24/P6X cells-and HFF and IF cells. OUMS-24/P6X cells and IF cells were immortalized by a dominant-negative p53 gene and the papilloma E6/ E7 gene, respectively. The paired cells were examined for p53 and p21 induction upon DNA-damaging agents to test the integrity of p53 functions (Figure 6a ). Parent cells bearing the wild-type p53, OUMS-24 and HFF cells, induced p53 and p21 protein upon cisplatin and etoposide treatments, although the induced levels and the patterns were different in the cell lines and the agents. The upregulation, however, was not observed in OUMS-24/ P6X: stable p53 expression due to decreased degradation of the mutated p53 and no p21 induction were detected. The induction levels in IF cells were less significant compared with HFF cells. These data showed that p53-mediated pathways were intact in the parent cells, but impaired in the immortalized cells. Such deficits in the p53-mediated pathways are functionally equivalent to p53 mutated conditions, suggesting that the immortalized cells can represent a tumor-like status from a standpoint of the p53 pathways. We also found that the CAR level of OUMS-24/P6X cells was greater than that of OUMS-24 cells (Figure 6b ) in contrast with the esophageal carcinoma cells, which had greater CAR expression in those with wild-type p53. CD51 expression levels were not different between the paired cell lines. The Ad infectivity was examined with Ad-GFP to show that OUMS-24/P6X cells were better than OUMS-24 cells in the infectivity (Figure 6c ). Ad-p53-mediated cytotoxicity was also greater in OUMS-24/P6X cells than in OUMS-24 cells (Figure 6d ). These data suggested that the increased susceptibility of OUMS-24/P6X cells to Ad-p53 was due to the increased CAR expression and/or the disrupted p53 signal pathways. In contrast, the CAR levels of HFF and CAR-dependent Ad-p53 effects G Ma et al IF cells were similar, although the levels were low (Figure 6b ). The Ad infectivity to both cells was comparable (Figure 6c ) and the cytotoxicity with Adp53 to them was also similar despite different integrity of the p53 pathways (Figure 6d ). Moreover, both HFF and IF cells were relatively resistant to the cytotoxicity compared with OUMS-24/P6X cells. It could be partly due to the cell attributes such as distinctive activation of apoptotic pathways in different cell origins. These data collectively suggest that the Ad-p53-mediated cytotoxicity is related with the CAR levels of target cells rather than the endogenous p53 status.
Discussion
In this study, we examined the antitumor effects produced by Ad-p53 and Ad-delE1B55 on nine kinds of human esophageal carcinoma cells and analyzed the cytotoxic activities with respect to the Ad receptor expression and the status of the endogenous p53 gene. As both Ad belong to type 5 Ad, CAR and/or CD51 expression levels of target cells are crucial for the infectivity and the Admediated gene expression. Earlier studies also showed that the p53 status of target tumors was pivotal to both Ad-p53-mediated and Ad-delE1B55-mediated cytotoxic activities. 9, 10, 13 In this study, we showed that esophageal carcinoma cells with wild-type p53 were more susceptible to Ad-p53 than those with p53 mutation primarily due to the upregulated CAR expression and that Ad-delE1B55-mediated cytotoxicity was not linked with the CAR level or the p53 status.
Tumors with the p53 mutation deteriorate the downstream pathways and forced expression of wild-type p53 in the tumors can restore the authentic pathways resulting in apoptosis induction. In contrast, tumors with wild-type p53 often have functional defects in the upstream and/or the downstream pathways, and subsequently the overexpression of the wild-type p53 gene does not always activate the apoptotic pathways. Earlier studies supported the notion and revealed that tumors with the p53 mutation were sensitive to Ad-p53-mediated cytotoxicity compared with those with the wild type, 9,10 but other studies also showed contradictory results that the effects of Ad-p53 were independent of the endogenous p53 status. 11, 12 This study, however, showed that esophageal carcinoma cells with wild-type p53 were rather sensitive to Ad-p53. The subsequent analyses revealed that tumors with the wild type showed greater CAR levels than those with the mutation, raising the possibility that the greater Ad-p53-mediated cytotoxicity to tumors with the wild type was due to the elevated CAR expression. Several studies showed that Ad-p53 effects depended on the Ad infectivity 18, 19 and were influenced by the CAR, but not by the integrins expression level. 20, 21 Our data also revealed that Ad-p53-mediated cytotoxicity was linked with the CAR levels and Ad-GFP infectivity was primarily subjected to the CAR expression. The present data, however, does not rule out an association between the p53 status and Ad-p53-mediated antitumor effects as a multiple comparison test in this study revealed the positive correlation. Katayose et al. 9 showed that Adp53-mediated cytotoxicity was subjected to the endogenous p53 status irrespective of Ad infectivity. Moreover, a recent large-scaled clinical study tested multiple markers to predict the Ad-p53 efficacy and showed that Ad-p53 were beneficial to patients with p53-mutated head-andneck tumors rather than those with non-mutated p53.
22
Clinical studies can draw a conclusion of the possible correlation, but we also need careful evaluation of such clinical trials as Ad-p53 produced antitumor effects through induction of antiangiogenesis 23 and augmentation of immune responses, 24 which may not be directly linked with the p53 status.
The reason why esophageal carcinoma cells with the wild-type p53 gene expressed CAR at greater level than those with p53 mutation is currently unknown. We tested whether wild-type p53 increased a CAR level by infecting Ad-p53 to p53-mutated TE-10 and YES-5 cells, and found that p53 did not modulate the CAR level. We noticed that OUMS-24/P6X cells with a functional defect in the p53-mediated pathways were rather great at the CAR expression level compared with the parent cells. Moreover, transduction of OUMS-24/P6X cells with Adp53 did not alter the CAR level (data not shown), and upstream regulatory sequences of the CAR gene does not have putative p53-binding sequences, although the CAR regulatory region can be modified epigenetically. 25 These data collectively suggest that the expression of the wildtype p53 gene does not influence the CAR level. Asaoka CAR-dependent Ad-p53 effects G Ma et al et al., 21 however, showed contradictory data that transduction of a p53-mutated glioma cell line with Ad-p53 downregulated the CAR expression and the antisense upregulated the CAR level of a glioma cell line with wildtype p53. They also reported that glioma cells with p53 mutation expressed CAR at a greater level than those with the wild-type p53. Further investigations, therefore, are required to understand a possible relation between an endogenous p53 status and the CAR expression in other tumors and clinical specimens.
The present data suggested that a CAR level on target cells rather than the endogenous p53 status is a predictive marker of Ad-p53-mediated cytotoxicity. Analyses of a paired cell line, OUMS-24 and OUMS-24/P6X cells, could not conclude possible correlation between the cytotoxicity and the CAR level or the p53 status as OUMS-24/P6X cells were CAR-high and defective in the p53-mediated pathways. Cytotoxicity data with another paired cell line, HFF and IF cells, suggested that the p53 status was less critical in the cytotoxicity than the CAR level: Ad infectivity tested with Ad-GFP as well as the CAR level was similar; the cytotoxicity to both cells was also similar despite the differential p53 signal pathways. These data suggest that the CAR level is more influential to the Ad-p53 effectiveness than the p53 status.
Ad-delE1B55 preferentially replicate in tumors and the viral progenies from burst cells spread into tumors in the vicinity. Ad-delE1B55 can subsequently produce greater cytotoxic effects than non-replicative Ad; in fact, this study showed that Ad-delE1B55 in general produced greater antitumor effects than Ad-p53. Moreover, our data showed that the Ad-delE1B55-mediated cytotoxicity did not have any correlation with the receptor expression or the p53 status. Recent studies showed that the cytotoxicity was rather correlated to properties of target tumors, such as transportability of the viral transcripts into cytoplasm 15 and that such E1B-mediated function was substituted by modulating heat-shock proteins of the tumors. 26 A possible biomarker to predict the effects of Ad-delE1B55 remains uncharacterized and a large-scaled clinical study is one of the methods to clarify it.
This study on esophageal carcinoma cells suggests that the CAR expression level is a better predictive biomarker for Ad-p53-mediated cytotoxicity than the endogenous p53 status. Our clinical study with Ad-p53 for esophageal carcinoma, however, could not support the assumption because of its limited patient numbers. 4 Esophageal carcinoma cells with the wild-type p53 tend to express CAR better than those with mutated p53, which has not been evidenced by other types of tumors, and this putative relationship needs further studies with more esophageal specimens. We also believe that clinical studies conducted for other cancer types using Ad-p53 require re-evaluation of the efficacy from the standpoint of CAR expression levels. This study also implies that upregulated CAR levels with a pharmaceutical agent can improve Ad-p53-mediated cytotoxicity. Increased CAR levels were achieved by histone deacetylase inhibitors 8, 25 and tumor necrosis factor-a, 27 whereas dexamethasone decreased the level. 27 These molecules are intrinsically produced in cancer patients and administration of the agonists and the antagonists thereby can augment the antitumor effects of Ad-p53. Such combinatory use of the agents with Ad-p53 is an alternative to a current clinical protocol using chemotherapeutic agents and Ad-p53.
